Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. - Wikidata - awgldk - TriplyDB

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.

http://www.wikidata.org/entity/Q33534680

about

Myasthenia gravis Intravenous immunoglobulin for myasthenia gravis Intravenous immunoglobulin for myasthenia gravis Intravenous immunoglobulin for myasthenia gravis Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society Critical care neurology.Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines.Comparative analysis of therapeutic options used for myasthenia gravis.Treatment of myasthenia gravis.Intravenous immunoglobulin in neurological disease: a specialist review.EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.Plasma exchange for myasthenia gravis.Intravenous immune globulins: an update for clinicians.Clinical evaluation and management of myasthenia gravis.Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study.Myasthenia gravis: clinical, immunological, and therapeutic advances.IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.Intravenous immunoglobulin therapy in paraneoplastic neurological syndromes.Myasthenia gravis: Five new things.Clinical profile and outcome of myasthenic crisis in a tertiary care hospital: A prospective study Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity Treatment strategies for myasthenia gravis.Plasmapheresis for neurological disorders.Current and emerging treatments for the management of myasthenia gravis.A retrospective study of complications of therapeutic plasma exchange in myasthenia.The myasthenic patient in crisis: an update of the management in Neurointensive Care Unit.The expanding role of therapeutic antibodies.Intravenous immunoglobulin in the treatment of neurologic disorders.Predictors of extubation outcomes following myasthenic crisis.Double filtration plasmapheresis in the treatment of myasthenic crisis--analysis of prognostic factors and efficacy.Overview of myasthenia gravis.Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin.An Update on Myasthenic Crisis.Autoimmune Myasthenia Gravis: Recommendations for Treatment and Immunologic Modulation.IVIG and PLEX in the treatment of myasthenia gravis.Myasthenic Crisis.Myasthenia gravis.

P2860

Q21202960-8B8DC629-1D0C-4703-ABF2-BEF063F0EE2E Q24202443-08D39FA1-F267-43B7-B236-F9A0C00E48F5 Q24242078-B2A7D464-EC6D-422C-91DE-E3090DD20CFD Q24246185-4565DFA2-56EC-4AA8-844E-92D70A7129CA Q26765172-667C13C9-28FD-473D-85F7-82C9A5505C4B Q30307728-3DE3E710-FD56-451A-82F2-7AA678219627 Q33748109-381EE30B-A7E4-46CE-8290-C15477BBBC9A Q34024635-3E25D09F-CBD9-4314-8AD1-17BC95AC278D Q34142187-ADED05FA-0B11-495A-B72F-8D6120D260AE Q34574581-7A8CC2B4-4ADC-4181-9697-3DB1E6572C31 Q34597256-DE4A0653-874D-47DB-8EF5-23CD65A07C6C Q35041815-49A6233C-43FD-43EF-9D6A-C88FD65D99AC Q35542385-3198123C-E649-4DF4-A23E-35BD45721E17 Q35723879-C1ABC0CB-B2D8-465C-A7E7-ECADEEC102D2 Q35795404-EE7FE47A-277D-4130-9BCD-1055C36FAA40 Q36006116-51510C4C-07FE-483F-9037-B67FC26115F6 Q36164823-5D9E527C-F9CF-422A-8A85-431DDC0ADCFA Q36602775-C8008800-30E6-4420-9D5D-7DE2D4227D1B Q37040144-96AB8135-3D74-4726-8838-F43943902743 Q37046686-78BC5302-9668-48AB-8677-12A9CDDDCB82 Q37315963-C172FA2F-5F5E-4C90-B659-612E21C3EEF8 Q37483922-058E5CFD-3F3D-43A8-9243-5662F5C7EDF3 Q37600865-58B465BC-50CA-4384-B6DB-580D755BF7DA Q37918361-3141007A-D511-4D4C-8EC3-BC5533FFB93D Q38061307-EDC83B8B-F47B-4EDE-BAE9-8847DC650604 Q38154111-4A365E67-2AA7-400E-AFC0-49CD95271B9E Q38182645-AABDD660-2752-4CFC-8B95-53D3E3940516 Q38495457-A80ECCCB-6631-4330-B627-8FC5E377F64C Q39179335-E11604BB-7E74-44E9-BFBE-403E25A610CA Q43700040-624B2AD3-C39D-4BD6-9FFD-C26E34569C12 Q44367084-1D85F6A1-7F74-4B58-AB2F-D1D2E012F5A2 Q46838325-B96597F2-F711-4E3E-8EEC-43C3CAD10C75 Q47858661-C65C630F-1104-4A34-B3A1-82B2E0E04DFE Q47876814-2908E636-BA6D-40EE-ABE6-03E156F030D4 Q48326036-3127E3A8-5141-487A-B8AB-A17269D0C2B2 Q51639810-ED7E6D63-CE05-4FA8-ACFD-7F7748A19485 Q53167813-71E92941-6B33-4F86-BC07-EFEA3C2891A3

P2860

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.

http://www.wikidata.org/entity/Q33534680

description

1999 nî lūn-bûn

@nan

1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.

@ast

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.

@en

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.

@nl

type

label

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.

@ast

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.

@en

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.

@nl

prefLabel

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.

@ast

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.

@en

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.

@nl

P1433

Q33534680-9D1CF398-C59D-4874-B01E-18819DED9DE4

P1476

Q33534680-EC1F07F8-FEBA-440F-BB4A-8AC1DD11D063

P2093

Q33534680-563D58BE-3C3D-435F-B53C-78AD1A612D49

Q33534680-69383401-08AC-497F-A363-1A42A313D965

Q33534680-6ACC48C2-0274-4002-9855-B17D21CF1857

Q33534680-7E75CD36-20BB-4A4A-A8D0-E5253709901A

Q33534680-A02BBA26-58B4-45E0-A554-1B62AEABA042

Q33534680-B62ECB9E-5EA9-4019-A670-0809687CCC44

Q33534680-C71B3FF1-E2CF-4F80-9821-F16CA8961428

Q33534680-EAB5B53E-6372-4F2A-9109-263DB863C9FB

Q33534680-FB27251A-0D18-4C82-B03C-931463A0578B

P304

Q33534680-655556DE-1FC7-4B29-8412-9A169F0626E2

P31

Q33534680-85644307-BE1E-42D2-9B63-F064C735F41F

P356

Q33534680-A358EE02-61F7-45C2-A2DF-D7F4FFDD6022

P407

Q33534680-E8267397-FFCA-4D15-9B16-E173A2E2F890

P433

Q33534680-8952C346-2180-4721-92C9-4B7E66E37FAD

P478

Q33534680-452AC309-48B0-4694-91C0-5BD7788F82CF

P577

Q33534680-375CD0BD-FD04-4964-A72A-F69CBF8FD851

P698

Q33534680-526886B7-3854-4671-B05C-8ECA433D8FA0

P356

P1433

P1476

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.

@en

P2093

Akbar MS

http://www.w3.org/2001/XMLSchema#string

Choudhry MA

http://www.w3.org/2001/XMLSchema#string

Chua HC

http://www.w3.org/2001/XMLSchema#string

Krendel DA

http://www.w3.org/2001/XMLSchema#string

Leshner RT

http://www.w3.org/2001/XMLSchema#string

Mohammad Y

http://www.w3.org/2001/XMLSchema#string

Qureshi AI

http://www.w3.org/2001/XMLSchema#string

Ulatowski JA

http://www.w3.org/2001/XMLSchema#string

Yahia AM

http://www.w3.org/2001/XMLSchema#string

P304

629-632

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.52.3.629

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

1999-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10025801

http://www.w3.org/2001/XMLSchema#string